Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: Synthesis, characterizations, DFT calculations, cytotoxic assays and binding to a DNA model base

Journal of Inorganic Biochemistry

Volumn 103, Issue 9, 2009, Pages 1278-1287

  Roy, Sudeshna ^a   Westmaas, Joyce A ^a   Buda, Francesco ^a   Reedijk, Jan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Antitumor; Cytotoxicity in vitro; DFT; DNA model base; Flexible amines; Platinum; Time dependent NMR

Indexed keywords

AMINE; BIS(PYRIDINE 2 YL)AMINE; BIS(PYRIMIDINE 2 YL)AMINE; CARBOPLATIN; CATION; CHELATING AGENT; CHLORIDE; CIS DIAMMINE(2,2' DIPYRIDINE 2 YLAMINE)PLATINUM NITRATE; CIS DIAMMINE(2,2' DIPYRIMIDINE 2 YLAMINE)PLATINUM NITRATE; CIS DICHLORIDO(2,2' DIPYRIMIDINE 2 YLAMINE)PLATINUM; CIS DICHLORO(2,2' DIPYRIDINE 2 YLAMINE)PLATINUM; CISPLATIN; CISPLATIN DERIVATIVE; DNA BASE; GUANINE DERIVATIVE; LIGAND; OXALIPLATIN; PLATINUM DERIVATIVE; PYRIDINE; PYRIMIDINE; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DENSITY FUNCTIONAL THEORY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DNA BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CARBON ISOTOPES; CELL LINE, TUMOR; CHELATING AGENTS; CISPLATIN; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; GUANINE; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68949208414     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinorgbio.2009.07.004     Document Type: Article

References (53)

1. Jamieson E.R., and Lippard S.J. Chem. Rev. 99 (1999) 2467-2498
2. Kelland L. Nat. Rev. Cancer 7 (2007) 573-584
3. Kelland L. Expert Opin. Investig. Drugs 16 (2007) 1009-1021
4. Jung Y.W., and Lippard S.J. Chem. Rev. 107 (2007) 1387-1407
5. Wang D., and Lippard S.J. Nat. Rev. Drug Discov. 4 (2005) 307-320
6. Reedijk J. Proc. Nat. Acad. Sci. USA 100 (2003) 3611-3616
7. S. Roy, J.A. Westmaas, K.D. Hagen, G.P. van Wezel, J. Reedijk, 103 (2009) 1288-1297.
8. Brabec V., Kleinwachter V., Butour J.L., and Johnson N.P. Biophys. Chem. 35 (1990) 129-141
9. Brabec V. Prog. Nucleic Acid Res. 71 (2002) 1-68
10. Brana M.F., Cacho M., Gradillas A., de Pascual-Teresa B., and Ramos A. Curr. Pharm. Des. 7 (2001) 1745-1780
11. Yao W.B., Kavallieratos K., de Gala S., and Crabtree R.H. Inorg. Chim. Acta 311 (2000) 45-49
12. Li D.C., and Liu D.J. Cryst. Res. Technol. 39 (2004) 359-362
13. Tu C., Wu X.F., Liu Q., Wang X.Y., Xu Q., and Guo Z.J. Inorg. Chim. Acta 357 (2004) 95-102
14. Rauterkus M.J., Fakih S., Mock C., Puscasu I., and Krebs B. Inorg. Chim. Acta 350 (2003) 355-365
15. van Albada G.A., Mutikainen I., Turpeinen U., and Reedijk J. Inorg. Chem. Commun. 9 (2006) 1067-1070
16. van Albada G.A., Mutikainen I., Turpeinen U., and Reedijk J. J. Mol. Struct. 837 (2007) 43-47
17. S. Roy, J.A. Westmaas, F. Buda, J. Reedijk, J. Inorg. Biochem. (2009), doi:10.1016/j.jinorgbio.2009.07.003.
18. Dhara S.C. Ind. J. Chem. 8 (1970) 193-196
19. Price J., Schramm R., Wayland B., and Williams A. Inorg. Chem. 11 (1972) 1280-1284
20. M. Brown, in: WIN Plot : Simple and Easy Plotting, 2006.
21. Interrante L.V., and Messmer R.P. Inorg. Chem. 10 (1971) 1174-1178
22. Priqueler J.R.L., Butler I.S., and Rochon F.D. Appl. Spectrosc. Rev. 41 (2006) 185-226
23. Still B.M., Kumar P.G.A., Aldrich-Wright J.R., and Price W.S. Chem. Soc. Rev. 36 (2007) 665-686
24. ADF2007.01, in: ADF2007.01, SCM, Theoretical Chemistry, Vrije Universiteit, Amsterdam, The Netherlands, .
25. Guerra C.F., Snijders J.G., te Velde G., and Baerends E.J. Theor. Chem. Acc. 99 (1998) 391-403
26. Velde G.T., Bickelhaupt F.M., Baerends E.J., Guerra C.F., Van Gisbergen S.J.A., Snijders J.G., and Ziegler T. J. Comput. Chem. 22 (2001) 931-967
27. Becke A.D. Phys. Rev. A 38 (1988) 3098-3100
28. Lee C.T., Yang W.T., and Parr R.G. Phys. Rev. B 37 (1988) 785-789
29. van Lenthe E., Ehlers A., and Baerends E.J. J. Chem. Phys. 110 (1999) 8943-8953
30. Marcelis A.T.M., Erkelens C., and Reedijk J. Inorg. Chim. Acta 91 (1984) 129
31. Keepers Y.P., Pizao P.E., Peters G.J., Vanarkotte J., Winograd B., and Pinedo H.M. Eur. J. Cancer 27 (1991) 897-900
32. Diaconu C.V., Cho A.E., Doll J.D., and Freeman D.L. J. Chem. Phys. 121 (2004) 10026-10040
33. Hocking R.K., Deeth R.J., and Hambley T.W. Inorg. Chem. 46 (2007) 8238-8244
34. Aoki K., Salam M.A., Munakata C., and Fujisawa I. Inorg. Chim. Acta 360 (2007) 3658-3670
35. Garza-Ortiz A., Maheswari P.U., Siegler M., Spek A.L., and Reedijk J. Inorg. Chem. 47 (2008) 6964-6973
36. Kampf G., Willermann M., Freisinger E., and Lippert B. Inorg. Chim. Acta 330 (2002) 179-188
37. Komeda S., Lutz M., Spek A.L., Yamanaka Y., Sato T., Chikuma M., and Reedijk J. J. Am. Chem. Soc. 124 (2002) 4738-4746
38. Peacock A.F.A., Habtemariam A., Fernandez R., Walland V., Fabbiani F.P.A., Parsons S., Aird R.E., Jodrell D.I., and Sadler P.J. J. Am. Chem. Soc. 128 (2006) 1739-1748
39. Corral E., Hotze A.C.G., Magistrato A., and Reedijk J. Inorg. Chem. 46 (2007) 6715-6722
40. Lakomska I., Szlyk E., Sitkowski J., Kozerski L., Wietrzyk J., Pelczynska M., Nasulewicz A., and Opolski A. J. Inorg. Biochem. 98 (2004) 167-172
41. Berners-Price S.J., Ronconi L., and Sadler P.J. Prog. Nucl. Magn. Reson. Spectrosc. 49 (2006) 65-98
42. Alvarez M., Robey R., Sandor V., Nishiyama K., Matsumoto Y., Paull K., Bates S., and Fojo T. Mol. Pharmacol. 54 (1998) 802-814
43. Bracht K. Boubakari. R. Grunert, P.J. Bednarski, Anti-Cancer Drugs 17 (2006) 41-51
44. Bracht K., Liebeke M., Ritter C.A., Grunert R., and Bednarski P.J. Anti-Cancer Drugs 18 (2007) 389-404
45. Brodie C.R., Collins J.G., and Aldrich-Wright J.R. Dalton Trans. (2004) 1145-1152
46. Fisher D.M., Bednarski P.J., Grunert R., Turner P., Fenton R.R., and Aldrich-Wright J.R. ChemMedChem 2 (2007) 488-495
47. Jaramillo D., Buck D.P., Collins J.G., Fenton R.R., Stootman F.H., Wheate N.J., and Aldrich-Wright J.R. Eur. J. Inorg. Chem. (2006) 839-849
48. Jaramillo D., Collins J.G., Junk P., and Aldrich-Wright J.R. J. Inorg. Biochem. 96 (2003) 159
49. Kemp S., Wheate N.J., Buck D.P., Nikac M., Collins J.G., and Aldrich-Wright J.R. J. Inorg. Biochem. 101 (2007) 1049-1058
50. Wheate N.J., Brodie C.R., Collins J.G., Kemp S., and Aldrich-Wright J.R. Mini-Rev. Med. Chem. 7 (2007) 627-648
51. Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E., and Schutte M. Breast Cancer Res. Tr. 99 (2006) 97-101
52. Hollestelle A., Elstrodt F., Nagel J.H.A., Kallemeijn W.W., and Schutte M. Mol. Cancer Res. 5 (2007) 195-201
53. M. Gielen, R. Willem, A. Bouhdid, D.D. Vos, in, Dibutyltin bis(dihydroxybenzoates) and Compositions Containing these Compounds, Pharmachemie B.V. (Haarlem, NL), United States, 1996.